CBRE vs CPHI · P/E 43, rev $35.77B vs rev $4.1M
CBRE Group Inc Class A (CBRE) versus China Pharma Holdings Inc (CPHI) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
China Pharma Holdings Inc (CPHI) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported CPHI revenue for 2025-12-31 was $4.1M. Net income was -$3.2M. Revenue was down 8.5% from 2024-12-31 to 2025-12-31. CPHI currently screens at market cap $29.0M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. CPHI currently screens at market cap $29.0M.
Not investment advice. Open the CBRE and CPHI stock pages for the full models.
Not investment advice.